I-Mab (IMAB) Competitors $5.79 +1.02 (+21.38%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$5.74 -0.05 (-0.95%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMAB vs. STOK, LENZ, SNDX, SION, XERS, TSHA, ZYME, NUVB, ARDX, and AMPHShould you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Stoke Therapeutics (STOK), LENZ Therapeutics (LENZ), Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Xeris Biopharma (XERS), Taysha Gene Therapies (TSHA), Zymeworks (ZYME), Nuvation Bio (NUVB), Ardelyx (ARDX), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. I-Mab vs. Its Competitors Stoke Therapeutics LENZ Therapeutics Syndax Pharmaceuticals Sionna Therapeutics Xeris Biopharma Taysha Gene Therapies Zymeworks Nuvation Bio Ardelyx Amphastar Pharmaceuticals Stoke Therapeutics (NASDAQ:STOK) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do analysts rate STOK or IMAB? Stoke Therapeutics presently has a consensus price target of $29.00, suggesting a potential downside of 4.42%. I-Mab has a consensus price target of $7.33, suggesting a potential upside of 26.66%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88I-Mab 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility and risk, STOK or IMAB? Stoke Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Is STOK or IMAB more profitable? Stoke Therapeutics has a net margin of 26.25% compared to I-Mab's net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat I-Mab's return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.25% 18.32% 15.48% I-Mab N/A -19.65%-18.58% Which has higher valuation & earnings, STOK or IMAB? I-Mab has lower revenue, but higher earnings than Stoke Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$36.56M45.48-$88.98M$0.8535.69I-Mab$3.89M121.55-$22.23MN/AN/A Does the media refer more to STOK or IMAB? In the previous week, Stoke Therapeutics had 24 more articles in the media than I-Mab. MarketBeat recorded 29 mentions for Stoke Therapeutics and 5 mentions for I-Mab. I-Mab's average media sentiment score of 0.50 beat Stoke Therapeutics' score of 0.38 indicating that I-Mab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 7 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral I-Mab 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in STOK or IMAB? 38.4% of I-Mab shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by company insiders. Comparatively, 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryStoke Therapeutics and I-Mab tied by winning 7 of the 14 factors compared between the two stocks. Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAB vs. The Competition Export to ExcelMetricI-MabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$389.52M$3.36B$6.05B$10.30BDividend YieldN/A2.31%5.73%4.82%P/E RatioN/A22.0885.1427.10Price / Sales121.55478.69607.17133.24Price / CashN/A44.9825.7730.18Price / Book2.3410.3812.646.69Net Income-$22.23M-$52.47M$3.32B$276.55M7 Day Performance32.49%0.18%-0.07%-0.40%1 Month Performance41.56%13.95%8.70%6.53%1 Year Performance319.57%20.83%78.24%41.04% I-Mab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMABI-Mab2.7372 of 5 stars$5.79+21.4%$7.33+26.7%+355.9%$389.52M$3.89M0.00380Analyst UpgradeGap UpHigh Trading VolumeSTOKStoke Therapeutics2.9706 of 5 stars$26.81+4.9%$25.57-4.6%+156.3%$1.40B$36.56M31.54100LENZLENZ Therapeutics1.7496 of 5 stars$46.11-5.4%$49.60+7.6%+56.3%$1.39BN/A-24.27110SNDXSyndax Pharmaceuticals3.6151 of 5 stars$16.40+5.1%$39.22+139.2%-20.5%$1.34B$23.68M-4.22110SIONSionna Therapeutics2.6873 of 5 stars$29.25-2.5%$38.00+29.9%N/A$1.32BN/A0.0035XERSXeris Biopharma2.7511 of 5 stars$8.13-0.9%$7.08-12.9%+173.2%$1.32B$203.07M-38.71290TSHATaysha Gene Therapies2.3675 of 5 stars$4.42-7.1%$9.00+103.6%+151.2%$1.30B$8.33M-13.00180Gap UpZYMEZymeworks0.0662 of 5 stars$16.68-1.5%N/AN/A$1.27B$122.87M-17.20460Analyst UpgradeNUVBNuvation Bio2.7806 of 5 stars$3.77+1.6%$7.86+108.4%+62.3%$1.27B$7.87M-5.9860Analyst ForecastGap UpARDXArdelyx4.3325 of 5 stars$5.20-1.1%$11.70+125.0%-17.1%$1.27B$333.61M-22.6190News CoverageAMPHAmphastar Pharmaceuticals4.4996 of 5 stars$26.58-0.6%$31.60+18.9%-50.6%$1.24B$722.68M9.962,028 Related Companies and Tools Related Companies Stoke Therapeutics Alternatives LENZ Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Sionna Therapeutics Alternatives Xeris Biopharma Alternatives Taysha Gene Therapies Alternatives Zymeworks Alternatives Nuvation Bio Alternatives Ardelyx Alternatives Amphastar Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAB) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneInvestors are quietly piling into this secret AI stock Elon hates… It's one of those things you just need t...Economic Media | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
